

Addendum

Addendum: Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia**Simonetta I. Gaumont¹, Rama Abdin², Joel Costoya¹, Andrew V. Schally³ and Joaquin J. Jimenez¹**¹Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA²Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA³Veterans Affairs Medical Center, Miami, FL 33125, USA**Published:****Copyright:** © 2024 Gaumont et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has an addendum:** This article received a publication fee waiver.Original article: Oncotarget. 2024; 15:248–254. <https://doi.org/10.18632/oncotarget.28579>